MLYS · Mineralys Therapeutics Inc
United States · RS rating 10 · As of 2026-11-03
| Price | 15.99 USD |
|---|---|
| 1-day change | +2.8% |
| RS rating (overall / 1M / 3M / 12M) | 10 / 11 / 13 / 16 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 33 / 8 / 38 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +23.1% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +66.2% |
| Market cap (USD) | $2.3B |